StayHappi Pharmacy To Open 15,000 Pharmacy Stores In Next Four Years

  • News
  • June 28, 2021

Mumbai : StayHappi Pharmacy, a Delhi-based company offering generic medicines through retail and online pharmacy, which currently has 620 stores, is planning to open 15,000 pharmacy stores pan-India over the next four years.

“Currently we are trying to expand by 50 pharmacies a month. Our goal is to reach 1,000 by the end of this year. We will be able to impact the lives of 100 crore people in helping them reduce their monthly medicine expenditure,” the company stated.

“The Covid-19 pandemic has led to a severe economic downturn, impacting industries and businesses in a variety of ways. However, in these difficult times, online pharmacies emerged as one of the biggest beneficiaries during the lockdown. People chose to buy medicines online to reduce the risk of infection. As this sector grew exponentially during a pandemic, many retailers acquired in local online pharmacies,” stated Arushi Jain, executive director, StayHappi Pharmacy.

The Indian e- pharma market is all poised to touch US$ 2.7 billion in the next four years by 2023 from about US$ 360 million at present, according to a new EY report ‘e-pharma: delivering healthier outcomes’.

The company stated that it is able to limit the unproductive costs on marketing, promotion, supply chain, freebies and other expenses and to pass on the benefit of cost curtailment to the consumers, through direct supply retail chain, throughout the country.

The company stated that pandemic unmistakably showed how the physical and online e-pharmacy need to work and both play a critical part in improving admittance to quality and moderate prescriptions the nation over.

StayHappi Pharmacy is an initiative of SarvaGunAushdhi Private Limited and provides medicines with their molecule name and not by the brand name, where patients will have the power to choose the right medicine and make a smart choice. With StayHappi Pharmacy, patients have the power to choose quality generics medicines across all therapeutic segments at prices that are 30%-90% less than the commonly retailed price of the same medicine in India.

Related Posts

13 Years after Oxytocin Order, HC Seeks Compilance Status

GWALIOR: The Gwalior Bench of the Madhya Pradesh High Court has directed the state government to submit a comprehensive compliance status report. This order addresses the implementation of the court’s…

Centre Pushes Haryana to Fast-Track AIIMS Rewari

New Delhi | August 18, 2025 — The Union government has urged Haryana to speed up work on AIIMS Rewari (Majra) and resolve on-ground hurdles so the institute can open…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

Excellence of Accredited Hospitals to be judged on how Friendly they are with Patients

WHO launches new primary health care course to strengthen health systems globally

WHO launches new primary health care course to strengthen health systems globally

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A